Milestone Pharmaceuticals Inc.宣布,其用于治疗阵发性室上性心动过速(PSVT)的鼻喷雾剂Etripamil的上市授权申请,已获得欧洲药品管理局(EMA)的正式受理。这一关键进展标志着该药物在欧洲监管审批流程中迈出了重要一步。
Milestone Pharmaceuticals Inc.宣布,其用于治疗阵发性室上性心动过速(PSVT)的鼻喷雾剂Etripamil的上市授权申请,已获得欧洲药品管理局(EMA)的正式受理。这一关键进展标志着该药物在欧洲监管审批流程中迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.